Cd73 compounds
US-2023183189-A1 · Jun 15, 2023 · US
CD73 compounds
US12110294B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12110294-B2 |
| Application number | US-202117243911-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 29, 2021 |
| Priority date | May 1, 2020 |
| Publication date | Oct 8, 2024 |
| Grant date | Oct 8, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides pyrimidine dione compounds of Formula Iand pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: 2. The compound of claim 1 , which is: or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. 4. The pharmaceutical composition of claim 3 , further comprising one or more additional therapeutic agents. 5. The pharmaceutical composition of claim 4 , wherein the additional therapeutic agent is independently an anti-neoplastic agent, chemotherapy, radiation therapy, or resection therapy. 6. The pharmaceutical composition of claim 5 , wherein the additional therapeutic agent is independently rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, nivolumab, atezolizumab or ipilimumab. 7. The pharmaceutical composition of claim 5 , wherein the additional therapeutic agent is a PD-1 or PD-L1 inhibitor.
Assignees
Inventors
Classifications
against receptors, cell surface antigens or cell surface determinants · CPC title
Antineoplastic agents · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
specific for metastasis · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12110294B2 cover?
- The present disclosure provides pyrimidine dione compounds of Formula Iand pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).